Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly, AstraZeneca Target Alzheimer’s
by Rick Mullin
September 22, 2014
| A version of this story appeared in
Volume 92, Issue 38
AstraZeneca and Eli Lilly & Co. have agreed to jointly develop and commercialize AstraZeneca’s AZD3293, an oral β-secretase cleaving enzyme (BACE) inhibitor, as a potential treatment for Alzheimer’s disease. Lilly will pay AstraZeneca $50 million up front with additional milestone payments of up to $500 million. The two companies will share the cost of development and commercialization, with Lilly leading clinical development. BACE is an enzyme associated with the development of amyloid-β, a plaque that accumulates in the brain with the progression of Alzheimer’s disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter